You’re invited to join the Clinical TMS Society for this installment of our Grand Rounds Webinar Series:
Individualized TMS Target Selection: Clinical Outcomes, Mechanisms of Action and Predictors of Response
Learning objectives:
1. Be able to understand the potential benefits of individualized Neuronavigated TMS;
2. Identify circuit-based predictors of TMS response;
3. Identify the circuit-based mechanisms of action of TMS antidepressant effects.
Date of Release: November 8, 2019
Date of Completion: November 7, 2021
Format: On-Demand
Cost: Members: $25 | Non-members $50 | Student Members FREE
Speakers: Joan Camprodon, MD, PhD
Dr. Camprodon is Chief of the Division of Neuropsychiatry at Massachusetts General Hospital and Assistant Professor of Psychiatry at Harvard Medical School. Clinically, he is the founding director of the MGH Transcranial Magnetic Stimulation (TMS) clinical service, a member of the Psychiatric Neurosurgery Committee and an attending physician in the departments of Psychiatry (Neuropsychiatry) and Neurology (Cognitive and Behavioral Neurology). He is board-certified in Psychiatry and Behavioral Neurology & Neuropsychiatry.
Scientifically, he directs the Laboratory for Neuropsychiatry and Neuromodulation. His research uses multimodal combinations of neuroimaging and brain stimulation to investigate neural circuitry and plasticity in a translational manner. His laboratory works with a wide range of noninvasive and invasive neuromodulation techniques including transcranial current stimulation (tCS), transcranial magnetic stimulation (TMS), electroconvulsive therapy (ECT) and deep brain stimulation (DBS) among others. He also uses functional and structural MRI, EEG and innovative simultaneous combinations of TMS and tDCS with neuroimaging. Dr. Camprodon is interested in understanding basic circuit properties of human neural networks and how maladaptive plastic changes lead to neuropsychiatric disorders. Critical efforts are geared towards applying the paradigms and methods of human systems neuroscience to develop high-impact clinical tools, identify targets for therapeutic action and design individualized image-guided neuromodulation treatments.